Silymarin in COVID-19 Patients Admitted to Hospital With Elevated Liver Enzymes
Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
Of patients admitted to an internal medicine ward with internistic diagnosis/es together with
COVID-19, substantial proportion has elevated liver enzymes. silymarin / silibinin (milk
thistle extract) has been approved as an add-on therapy in various acute and chronic liver
diseases; moreover, there is evidence to suggest that it's dual effect (anti-viral and
immune-modulatory) might be of benefit in patients infected with SARS-CoV-2. As there is no
effective/approved pharmacotherapy for COVID-19, a pilot study with Silymarine in
hospitalised patients has been undertaken
Phase:
Phase 4
Details
Lead Sponsor:
F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica